Zetagen
Our Company
The Science
Therapies
Oncology
OverviewZetaMet™ (Zeta-BC-003)ZetaMet-P™ (Zeta-PC-004)ZetaMAST™ (Zeta-MBC-005)ZetaBase®
Musculoskeletal
Overview
News
Press Releases
Publications
Walk With You
Research
Overview
Regulatory Status
Clinical Trials
Contact Us

News

Keep Up to date with our latest news and press releases

Zetagen Therapeutics Expands IP Portfolio, Achieving a Milestone of 64 Worldwide Patents in 2024

January 8, 2025, (Syracuse, New York) – Zetagen Therapeutics, Inc., a private, clinical stage, biopharmaceutical company focused on developing proprietary carriers delivering tumoricidal therapies for metastatic and primary breast cancer, which may minimize patient side effects with the potential to increase survival rates, announced today in 2024 they nearly doubled their worldwide IP portfolio to 64 patents, spanning across 36 countries including the United States, Europe, Canada, Australia, Japan, United Kingdom, India, Sweden and Switzerland.
Read More

Zetagen Therapeutics Shares In-vivo Dose Optimization Data of ZetaMAST™ (Zeta-MBC-005) Metastatic Breast Cancer in Liver

December 10, 2024, (Syracuse, New York) – Zetagen Therapeutics, Inc., a private, clinical stage, biopharmaceutical company focused on developing proprietary carriers delivering tumoricidal therapies for metastatic and primary breast cancer, minimizing patient side effects with the potential to increase survival rates, announced today in-vivo results of their dose optimization study of ZetaMAST™ (Zeta-MBC-005).  Zetagen identified two concentrations of Zeta-MBC-005 which demonstrated superior effectiveness, reduction in tumor burden, and increased survival rate over control Doxorubicin.
Read More

Empire State Development Announces More Than $4M Awarded to Small Businesses Through NYSTAR’s Innovation Matching Grants Program

Friday, November 15, 2024 – Empire State Development’s Division of Science, Technology and Innovation (NYSTAR) today announced that 35 businesses have been awarded $4,637,226.00 in Round 1 & 2 of its new Innovation Matching Grants program.
Read More

Zetagen Therapeutics Announces First Patients Enrolled in Phase 2a Clinical Study of ZetaMet™ (Zeta-BC-003) Metastatic Breast Cancer

November 12, 2024, (Syracuse, New York) – Zetagen Therapeutics, Inc., a private, clinical stage, biopharmaceutical company focused on developing breakthrough therapies, via local administration, for metastatic breast cancer to bone and soft tissues, announced today that the first two patients have enrolled in the phase 2a study, which will evaluate ZetaMet™ (Zeta-BC-003) in the treatment of spinal metastatic lytic breast cancer lesions (ClinicalTrials.gov #NCT05280067).
Read More

New Data Published in JAAOS Demonstrates Breakthrough Therapy ZetaFuse® as a Potential Treatment for Degenerative Disc Disease in Late-Stage Cancer Patients

September 24, 2024, (Syracuse, New York) – Zetagen Therapeutics, a private, clinical-stage, biopharmaceutical company developing breakthrough therapies via local administration for metastatic and primary cancers to bone and other organs, today announced publication of clinical data in the peer-reviewed Journal of the American Academy of Orthopaedic Surgeons (JAAOS) on ZetaFuse® (Zeta-ZF-002) for the treatment of multi-level DDD in a Stage 4 lung cancer patient.
Read More

Zetagen Announces the Appointment of Debasish (Debu) Tripathy M.D. to its Advisory Board

March 18, 2024, (Syracuse, New York) – Zetagen Therapeutics, a private, clinical-stage, biopharmaceutical company dedicated to developing breakthrough therapies via local administration for the treatment of metastatic and primary cancers in bone and soft tissue organs, today announced the appointment of Debasish (Debu) Tripathy, MD to its advisory board. Dr. Tripathy is Professor and Chairman, Department of Breast Medical Oncology, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center.
Read More

Zetagen Receives Approval in Australia to Begin Pilot Study of ZetaFuse® Bone Graft to Treat Cervical Degenerative Disc Disease

November 6, 2023, (Syracuse, New York) - Zetagen Therapeutics, a private, clinical-stage, biopharmaceutical company focused on driving breakthrough innovation in the treatment of metastatic cancers to bone and soft tissue organs as well as osteologic interventions, today announced its approval from the Human Research Ethics Committee (HREC) of Australia to begin a pilot study using its novel therapy ZetaFuse® bone graft for the treatment of cervical degenerative disc disease. The pilot study is a randomized, open-label, two-level cervical program which will examine the safety and efficacy of ZetaFuse® bone graft in patients undergoing anterior cervical discectomy and fusion (ADCF) surgery.
Read More

Zetagen Announces Publication in Pain Management of Early Data Using ZetaMet™ (Zeta-BC-003) as a Potential Treatment for Bone Metastases

October 10, 2023, (Syracuse, New York) - Zetagen Therapeutics, a private, clinical-stage, biopharmaceutical company focused on driving breakthrough innovation in the treatment of metastatic cancers to bone and soft tissue organs as well as osteologic interventions, today announced publication of early, human clinical data in the peer-reviewed journal Pain Management on ZetaMet™ (Zeta-BC-003) for the treatment bone metastases.
Read More

Zetagen Therapeutics Secures 9.79 Million USD Series B Funding Raise for Advancement of ZetaMet™ (Zeta-BC-003) and ZetaMAST™ (Zeta-MBC-005)for Treatment of Metastatic Bone and Soft Tissue Lesions

August 11, 2023, (Syracuse, New York) - Zetagen Therapeutics, a private, clinical-stage, biopharmaceutical company focused on driving breakthrough innovation in the treatment of metastatic cancers to bone and soft tissue organs as well as osteologic interventions, today announced the close of $9.79 million USD Series B funding round.
Read More
1 2 3
By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively.
OK